Should I Buy INO? INO 2026 Analysis

Should You Buy Inovio Pharmaceuticals Inc (INO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.610

1 Day change

5.23%

52 Week Range

2.980

Analysis Updated At

2026/01/26

Inovio Pharmaceuticals Inc (INO) is not a strong buy for a beginner, long-term investor at this time. The stock shows bearish technical indicators, weak financial performance, and lacks significant positive catalysts. While the analyst rating is optimistic with a raised price target, the company's fundamentals and trading sentiment do not align with a strong buy recommendation.

Technical Analysis

The stock exhibits bearish technical indicators: MACD is below 0 and negatively contracting, RSI is neutral at 34.428, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The price is trading below key support levels, with S1 at 1.486 and S2 at 1.432.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options data indicates a strong bias towards calls, but overall trading volume is low, and implied volatility is high (132.79), suggesting uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

Analyst Edward Tenthoff raised the price target to $6 from $5, citing sufficient cash to fund operations through Q3 2026, which aligns with the potential approval of INO-3107.

Neutral/Negative Catalysts

No recent news, no significant hedge fund or insider trading activity, and no recent congress trading data. The stock's financials show weak performance, with negative net income and declining EPS.

Financial Performance

In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 80.79% YoY but remains negative at -$45.5M. EPS dropped by -2.25% YoY to -0.87. Gross margin is 100% but reflects no revenue generation.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Piper Sandler's analyst maintains an Overweight rating and raised the price target to $6, citing sufficient cash reserves to fund operations through Q3 2026.

3 Analyst Rating

Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3 USD and a high forecast of 13 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 1.530

Low

Averages

7.33

High

Current: 1.530

Low

Averages

7.33

High

Piper Sandler

Edward Tenthoff

Overweight

maintain

$5 -> $6

AI Analysis

2025-11-14

Reason

Piper Sandler

Edward Tenthoff

Price Target

$5 -> $6

AI Analysis

2025-11-14

maintain

Overweight

Reason

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Inovio to $6 from $5 and keeps an Overweight rating on the shares. The firm notes the company ended Q3 with cash of $50.8M and subsequently raised gross proceeds of $28.75M bringing pro forma cash to $77.3M, expected to fund operations into Q3 2026 through INO-3107 approval.

Piper Sandler

Edward Tenthoff

initiated

2025-07-09

Reason

Piper Sandler

Edward Tenthoff

Price Target

2025-07-09

initiated

Reason

Piper Sandler analyst Edward Tenthoff initiated coverage of Inovio with an Overweight rating and $5 price target. The company is is developing DNA-encoded medicines to treat cancer, infectious and rare diseases, the analyst tells investors in a research note. The firm says INO-3107, being developed to treat recurrent respiratory papillomatosis caused by human papillomavirus, was well tolerated and achieved robust clinical efficacy in a Phase I/II study.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INO

Unlock Now

INO Should I Buy

INO Should I Buy

Should You Buy Inovio Pharmaceuticals Inc (INO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch